← Back to Search

Albumin

Albutein for Cirrhosis (PRECIOSA Trial)

Phase 3
Waitlist Available
Research Sponsored by Grifols Therapeutics LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects with diagnosis of liver cirrhosis
Subjects who have been hospitalized for acute decompensation of liver cirrhosis with ascites
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

PRECIOSA Trial Summary

This trial will compare the standard treatment for decompensated cirrhosis plus Albutein to standard treatment alone, in order to evaluate the efficacy of Albutein.

Who is the study for?
Adults with decompensated liver cirrhosis and ascites, not currently in acute-on-chronic liver failure (ACLF), can join this trial. They must have a CLIF-C AD score over 50 and be stable post-hospitalization for liver issues. Excluded are those with ACLF at screening, severe lung or heart conditions, recent other trials participation, active drug addiction (excluding alcohol/marijuana), ongoing infections like SBP or COVID-19, kidney failure, certain therapies like TIPS/shunts or dual antiplatelets/anticoagulants.Check my eligibility
What is being tested?
The study is testing the effectiveness of adding Albutein 20% Injectable Solution to standard medical treatment compared to standard treatment alone in managing decompensated cirrhosis and ascites. It's a phase 3 trial where participants are randomly assigned to one of the two groups.See study design
What are the potential side effects?
Potential side effects include allergic reactions to albumin for those sensitive to it. Since specific side effects aren't listed here, general risks may involve discomfort at injection sites and possible interactions with existing medications.

PRECIOSA Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with liver cirrhosis.
Select...
I was hospitalized for a severe worsening of liver cirrhosis with fluid buildup.
Select...
I have worsening cirrhosis from hepatitis C and won't get antiviral therapy during the study.

PRECIOSA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to liver transplantation or death (whichever comes first) through 1 year after randomization in subjects receiving SMT + Albutein 20% administration versus subjects receiving SMT alone
Secondary outcome measures
Time to death through 1 year after randomization in subjects receiving SMT + Albutein 20% administration versus subjects receiving SMT alone
Time to death through 3 months after randomization in subjects receiving SMT + Albutein 20% administration versus subjects receiving SMT alone
Time to death through 6 months after randomization in subjects receiving SMT + Albutein 20% administration versus subjects receiving SMT alone
+4 more

PRECIOSA Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Standard Medical Treatment + Albutein 20%Experimental Treatment2 Interventions
Standard Medical Treatment plus Albutein 20% administrations
Group II: Standard Medical TreatmentActive Control1 Intervention
The sites will follow the Standard Medical Treatment as per their Standard of Care.

Find a Location

Who is running the clinical trial?

Grifols Therapeutics LLCLead Sponsor
57 Previous Clinical Trials
5,398 Total Patients Enrolled
Instituto Grifols, S.A.Industry Sponsor
29 Previous Clinical Trials
5,017 Total Patients Enrolled

Media Library

Albutein 20% Injectable Solution (Albumin) Clinical Trial Eligibility Overview. Trial Name: NCT03451292 — Phase 3
Cirrhosis Research Study Groups: Standard Medical Treatment + Albutein 20%, Standard Medical Treatment
Cirrhosis Clinical Trial 2023: Albutein 20% Injectable Solution Highlights & Side Effects. Trial Name: NCT03451292 — Phase 3
Albutein 20% Injectable Solution (Albumin) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03451292 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the FDA's stance on Standard medical treatment?

"Standard medical treatment received a score of 3."

Answered by AI

What is the most usual form of medical care given for this condition?

"Peritonitis is most commonly treated with standard medical interventions. However, this treatment can also be used to address various other conditions such as liver failure and respiratory distress syndrome in adults."

Answered by AI

Are there other examples in the medical literature of Standard medical treatment?

"The first clinical trial for standard medical treatment was conducted in 2007 at Herbert Irving Pavillion 11th Floor. Since then, a total of 178 clinical trials have been completed. As of now, there are 139 active trials recruiting patients; many of these are based in Columbia, South carolina."

Answered by AI

What is the enrollment for this clinical trial?

"That is correct. The information available on clinicaltrials.gov indicates that this study was originally posted on July 24th, 2018 and is still recruiting participants. Currently, 410 individuals are needed for the trial which is being conducted at 9 different locations."

Answered by AI

Has a trial like this been conducted before?

"Standard medical treatment has a long research history, with the first clinical trial taking place in 2007. That initial study was sponsored by Celgene Corporation and involved 47 patients. After receiving Phase 1 & 2 drug approval in 2007, there are now 139 live studies involving Standard medical treatment across 33 countries and 918 cities"

Answered by AI

Could you please inform me how many different locations are conducting this trial at the moment?

"There are many medical centres participating in this trial, some of which include University of Missouri Hospital, University of Ottawa, and University Health Network - Toronto General Hospital."

Answered by AI

Are there any unfilled positions in this trial for potential participants?

"That is correct. The clinical trial, which was originally posted on July 24th, 2018 and updated on October 28th, 2020, is actively recruiting participants. 9 different locations are looking for a total of 410 individuals to fill the open slots."

Answered by AI

Who else is applying?

What state do they live in?
Texas
Iowa
How old are they?
18 - 65
What site did they apply to?
Dallas VA Medical Center
Azienda Ospedaliero-Universitaria di Modena
Azienda Ospedaliera di Padova
What portion of applicants met pre-screening criteria?
Met criteria
~0 spots leftby May 2024